The United States Patent and Trademark Office (USPTO) has issued Civitas Therapeutics US Patent No. 8,545,878, with an expiration date of November 16, 2032, for a patent titled “Capsules containing high doses of levodopa for pulmonary use.” Civitas says that it now has more than 115 patents related to its CVT-301 inhaled L-dopa for the treatment of Parkinson’s disease.
Civitas CEO and co-founder Glenn Batchelder commented, “This newly issued patent further fortifies and extends our robust patent estate covering CVT-301. The Arcus platform’s unique capabilities and versatility provide a wealth of opportunities for continued innovation thereby broadening and deepening our patent estate around both the platform and CVT-301.”
CVT-301 is currently in Phase 2b clinical development. The company recently said that it also intends to “explore additional opportunities to leverage the Arcus platform.”
Read the Civitas press release.
